Allogene Therapeutics Stock News

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...

Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in,...

Vident Investment Advisory LLC trimmed its holdings in shares of Allogene Therapeutics Inc (NASDAQ:ALLO) by 33.5% during the 2nd quarter, according to the company in its most recent 13F filing with th

Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.

* Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechno

BidaskClub lowered shares of Allogene Therapeutics (NASDAQ:ALLO) from a buy rating to a hold rating in a research note published on Friday, BidAskClub reports. Several other brokerages also recently c

Vident Investment Advisory LLC decreased its holdings in shares of Allogene Therapeutics Inc (NASDAQ:ALLO) by 33.5% during the second quarter, according to its most recent filing with the Securities a

Notch Therapeutics Inc., a biotechnology company creating universally compatible, off-the-shelf T cell therapies for cancer and immune disorders from renewable stem cell sources, is pleased to announc

We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

The SAB comprises experts across oncology, immunology, cell therapy, and drug discovery and development. “We are privileged to welcome Drs. Gajewski and Grupp to our Scientific Advisory Board,”

Allogene Therapeutics Inc (NASDAQ:ALLO) was the target of a large decline in short interest in June. As of June 30th, there was short interest totalling 11,490,000 shares, a decline of 13.3% from the

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest

Allogene Therapeutics Inc (NASDAQ:ALLO) major shareholder Group Holdings (Sbs) Advis Tpg sold 500 shares of the firm’s stock in a transaction on Friday, June 26th. The shares were sold at an average

Rexgenero, a regenerative medicine company appoints Dr Gilbert Wagener as Senior Vice President and Chief Medical Officer.

Shares of Allogene Therapeutics Inc (NASDAQ:ALLO) moved lower by 2% from the previous closing price. A Form 4 filing filed with the SEC on Monday, June 29 showed that Tpg Group Holdings Sbs) Advisors,